# FIRST LIGHT

03 May 2023

## RESEARCH

### BOB ECONOMICS RESEARCH | BONDS WRAP

Fortnightly review

### KOTAK MAHINDRA BANK | TARGET: Rs 2,122 | +10% | HOLD

Healthy quarter but positives priced in

**Daily macro indicators**

| Ticker | 28-Apr | 01-May | Chg (%) |
|---|---|---|---|
| US 10Y yield (%) | 3.42 | 3.57 | 15bps |
| India 10Y yield (%) | 7.10 | 7.12 | 2bps |
| USD/INR | 81.84 | 81.83 | 0.0 |
| Brent Crude (US$/bbl) | 79.5 | 79.3 | (0.3) |
| Dow | 34,098 | 34,052 | (0.1) |
| Hang Seng | 19,840 | 19,895 | 0.3 |
| Sensex | 60,649 | 61,112 | 0.8 |
| **India FII (US$ mn)** | **26-Apr** | **27-Apr** | **Chg ($ mn)** |
| FII-D | 113.9 | 66.2 | (47.7) |
| FII-E | 176.2 | 482.0 | 305.8 |

Source: Bank of Baroda Economics Research

## SUMMARY

### INDIA ECONOMICS: BONDS WRAP

Global bond yields traded mixed in Apr'23 influenced by varied macros. In the US, while labour market and consumption demand remained buoyant, burgeoning budget deficit and contraction in manufacturing activity posed concerns. However, market is pricing in a 25bps rate hike by Fed in the coming policy with expectations of prolonged pause post that as the OIS papers reflect the same. This comforted US sovereign 10Y yield to some extent in Apr'23. On the other hand, 10Y yields in UK and Germany inched up as the rhetoric of inflation posed concerns. India's 10Y yield have exhibited quite a bit of downswing in Apr'23, falling by 19bps. This was post RBI's surprise move of a pause, defying market expectations of another 25bps hike.

Click here for the full report.

### KOTAK MAHINDRA BANK

- Q4 PAT grew 26% YoY backed by a strong topline and lower opex; provisions stayed flat
- Thrust on lucrative unsecured loan to keep NIM above 5%, though opex likely to remain a drag
- Assume coverage with HOLD for a TP of Rs 2,122

Click here for the full report.

**BOBCAPS Research**
research@bobcaps.in

## BONDS WRAP

02 May 2023

# Fortnightly review

**Dipanwita Mazumdar**
Economist

**Global bond yields traded mixed in Apr'23 influenced by varied macros. In the US, while labour market and consumption demand remained buoyant, burgeoning budget deficit and contraction in manufacturing activity posed concerns. However, market is pricing in a 25bps rate hike by Fed in the coming policy with expectations of prolonged pause post that as the OIS papers reflect the same. This comforted US sovereign 10Y yield to some extent in Apr'23. On the other hand, 10Y yields in UK and Germany inched up as the rhetoric of inflation posed concerns. India's 10Y yield have exhibited quite a bit of downswing in Apr'23, falling by 19bps. This was post RBI's surprise move of a pause, defying market expectations of another 25bps hike.**

A lower than expected inflation reading in consonance with favourable oil price and improved appetite for sovereign securities, supported yields in the domestic market. Interestingly, yields across all tenor fell in Apr'23; even the short end curve exhibiting quite a bit of correction, which was not observed in the past two months. Thus the entire yield curve of India shifted downward. Liquidity remained in surplus to the tune of Rs 1.6 lakh crore, supported by RBI's fine tuning through SDF. We expect India's 10Y yield to trade with a downward bias in the range of 7.10-7.15% in May'23. Comfort would come from softening of CPI data in Apr'23, as major high frequency domestic price data are reflecting the same.

**Global yields gave mixed signals in Apr'23:**

- Both risk on and risk off sentiments conveyed by varied macro data points globally led sovereign 10Y yields in major economies to trade differently. While in major economies such as US, China and India, 10Y yields moderated; on the other hand for UK, Japan and Germany, it inched up.

- In the US, while personal consumption demand and labour market conditions remained buoyant, burgeoning budget deficit, elevated core PCE and contraction in manufacturing activity posed concerns about state of the economy and inflation. CME Fed watch tool is attaching a 95.1% probability for a 25bps rate hike in the coming policy. However, post that money market is pricing in a pause and the 1 Year ahead OIS paper is signaling a rate cut from Fed. US 10Y yield fell by 5bps in Apr'23 compared to Mar'23. In China, softening CPI and PPI print despite some breather in economic activity raised expectations of more monetary stimulus, thus its 10Y yield fell by 8bps.

- On the other hand, in UK 10Y yield firmed up by 23bps supported by firming up of inflation numbers and also robust macro data such as consumer confidence, retail sales and flash services PMI reading. BoE Deputy Governor Dave Ramsden highlighted inflation as key risk. In Japan 10Y yield firmed up by 4bps as its monetary policy statement included the term "broad- perspective review of monetary policy", under its new Governor, which has sparked a bit of anticipation regarding its recourse of ultra-low rates.

**HOLD**
**TP: Rs 2,122 | ▲ 10%**

## KOTAK MAHINDRA BANK

| Banking | 02 May 2023

# Healthy quarter but positives priced in

- **Q4 PAT grew 26% YoY backed by a strong topline and lower opex; provisions stayed flat**
- **Thrust on lucrative unsecured loan to keep NIM above 5%, though opex likely to remain a drag**
- **Assume coverage with HOLD for a TP of Rs 2,122**

**Ajit Agrawal**
research@bobcaps.in

**Healthy Q4:** KMB delivered healthy Q4FY23 PAT growth of 26% YoY to Rs 35bn supported by higher NII (+8% QoQ, +35% YoY) and lower opex (C/I ratio down 641bps QoQ). NIM (calc.) expanded 11bps QoQ to 5.3% backed by strong growth in the high-yield retail book (unsecured portfolio contributes 10% per management). Credit grew 3% QoQ (18% YoY) aided by retail while the corporate book was muted. Deposits rose 5% QoQ led by CASA, though the CASA ratio slipped 50bps QoQ to 52.8%. Lower opex boosted PPOP growth to 39% YoY. Flat provisions led to credit cost of 20bps with improvement in GNPA/NNPA/PCR to 1.8%/0.4%/79%.

**Focus on unsecured book to sustain NIM:** KMB is targeting growth in the retail business, which could front-load costs over the next 3-4 quarters. Despite higher expenses and an uptick in cost of funds from deposit repricing, management expects to sustain margins via a gradual increase in business volumes, specifically from the unsecured retail book where it plans to expand credit share to the mid-teens from sub-10% currently. We model for NIM at 4.7% over FY24-FY25, assuming a credit /deposit CAGR of 18%/17% over FY22-FY25 driven by granularity. Strong core and non-core income is likely to result in a PPOP CAGR of 18.2%.

**Asset quality stable:** KMB is among the best-in-class on the asset front in spite of a higher SME and retail book, though its focus on growing the unsecured book (prone to delinquency) could pose challenges in terms of quality and is a key monitorable. Although the bank has ample PCR of 79%, we expect the change in mix to raise credit cost down the line to 40bps in FY24/FY25 with GNPA/NNPA/PCR at 1.6%/0.4%/~77% for both years. KMB tops the list amongst peers in terms of CAR which stands at 22% (tier-1 at 20.6%).

**HOLD, TP Rs 2,122:** The stock is currently trading at a premium valuation of 2.6x FY25E P/ABV which is well above peers and captures KMB's high-margin business, healthy return ratios and stable asset quality, in our view. This apart, leveraging of the unsecured business would be key to watch given the change in succession plan in the near future. We assume coverage with HOLD for a TP of Rs 2,122, valuing the bank at 3.1x FY25E ABV (Gordon Growth Model) and adding in Rs 505/sh for subsidiaries.

### Key changes

| Target | Rating |
|---|---|
| ▲ | ▼ |

| | |
|---|---|
| Ticker/Price | KMB IN/Rs 1,921 |
| Market cap | US$ 46.6bn |
| Free float | 74% |
| 3M ADV | US$ 83.8mn |
| 52wk high/low | Rs 1,998/Rs 1,631 |
| Promoter/FPI/DII | 26%/39%/21% |

Source: NSE | Price as of 2 May 2023

### Key financials

| Y/E 31 Mar | FY23P | FY24E | FY25E |
|---|---|---|---|
| Net interest income | 21,552 | 24,496 | 28,056 |
| NII growth (%) | 28.1 | 13.7 | 14.5 |
| Adj. net profit (Rs mn) | 10,939 | 11,838 | 13,716 |
| EPS (Rs) | 55.1 | 59.6 | 69.0 |
| Consensus EPS (Rs) | 55.1 | 60.1 | 69.3 |
| P/E (x) | 34.9 | 32.2 | 27.8 |
| P/BV (x) | 4.6 | 4.0 | 3.5 |
| ROA (%) | 2.8 | 2.2 | 2.2 |
| ROE (%) | 17.9 | 13.3 | 13.5 |

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

### Stock performance




Source: NSE

**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

# Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**
Brand Name: **BOBCAPS**
Trade Name: **www.barodaetrade.com**
CIN: **U65999MH1996GOI098009**
Logo:

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Recommendation scale: Recommendations and Absolute returns (%) over 12 months**

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

**Analyst certification**

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

**Important disclosures**

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

**General disclaimers**

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.



**Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

**Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

**Distribution into the United Kingdom ("UK"):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as **"MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

**No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

**Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.